
As we look back on another year of activities, I would like to take the opportunity to thank all members of our Editorial Board, our reviewers, and, of course, the authors who have chosen to publish their work in Dermatopathology [...]
Chimeric antigen receptor (CAR) T cell therapy to treat solid tumors has seen limited success, partly due to tumor heterogeneity and antigen escape. These barriers remain major challenges, as heterogeneous tumors often consist of diverse populations of cancer cells, which can downregulate or lose the targeted antigens following the treatment, thereby evading CAR T cell recognition and killing. To address this challenge, we engineered CAR T cells to secrete bispecific T cell engagers (BTCEs) targeting epithelial cell adhesion molecule (EpCAM). EpCAM is a tumor-associated antigen widely expressed in epithelial-derived tumors but often considered "undruggable" by conventional targeted therapies due to its expression in normal epithelial cells. Secretion of the anti-EpCAM BTCEs by CAR T cells localizes BTCEs to the tumor site, preventing antigen escape while limiting systemic toxicity. This tactic successfully uses CAR T cells as carriers to restrict BTCE activity within the tumor microenvironment. Here, we show that in preclinical models, glypican-3 (GPC3)-, Delta-like ligand 3 (DLL3)-, and human epidermal growth factor receptor 2 completely eradicate heterogeneous tumors of epithelial origins and stop antigen escape. Our results highlight the versatility of this technology across various epithelia-originated carcinomas and imply that this strategy has significant translational potential to enhance solid tumor immunotherapy.
Secretory carcinoma is a low-grade malignant neoplasm characterized histologically by microcystic and tubular structures containing intraluminal secretions and molecularly by the frequent presence of an ETV6::NTRK3 fusion. It most commonly arises in the salivary glands and breast, whereas primary cutaneous secretory carcinoma is exceedingly rare. We report a case of secretory carcinoma arising in the skin of the right lower eyelid in an 82-year-old woman. A gradually enlarging nodule had been present for six months. Excision revealed a dermal tumor composed of mildly atypical polygonal cells forming microcystic and tubular structures with intraluminal secretions. The neoplastic cells expressed S100 protein, mammaglobin, MUC1, MUC4, GATA3, SOX10, and pan-TRK. Fluorescence in situ hybridization demonstrated fusion signals consistent with an ETV6::NTRK3 fusion. Taken together, these findings favored a diagnosis of secretory carcinoma rather than other adnexal malignancies, particularly apocrine and sebaceous carcinomas. This case illustrates the value of integrating morphology, immunohistochemistry, and appropriately interpreted molecular testing in the evaluation of rare eyelid adnexal tumors.
Eccrine syringofibroadenoma (ESFA) is a rare adnexal proliferation of acrosyringeal origin. Multiple, diffuse palmoplantar ESFA (eccrine syringofibroadenomatosis) is a recognized cutaneous marker of Schöpf–Schulz–Passarge syndrome (SSPS), a WNT10A-related ectodermal dysplasia, although ESFA-like changes may also arise reactively in chronic inflammatory dermatoses. We report a 66-year-old woman with a 10-year history of palmoplantar lesions clinically diagnosed as psoriasis and refractory to topical therapy, acitretin, adalimumab and ixekizumab. She also had long-standing diffuse alopecia and recurrent eyelid margin lesions previously treated with electrocoagulation. Examination showed erythematous, desquamative and fissured palmoplantar plaques, diffuse non-scarring alopecia and multiple cysts along both eyelid margins. Because of treatment failure and this atypical constellation, a palmoplantar biopsy was performed, revealing a reticulated eccrine syringofibroadenomatous (ESFA-like) proliferation with dilated eccrine ducts. This histological clue, interpreted together with keratoderma, hypotrichosis and eyelid margin cysts (the core features of SSPS), prompted targeted genetic testing, which identified a homozygous pathogenic WNT10A variant, c.321C>A p.(Cys107*), confirming SSPS. Apremilast 30 mg twice daily was followed by improvement in erythema, scaling and fissuring maintained after 24 months of follow-up. This case shows how recognition of ESFA-like changes in a biopsy from presumed refractory palmoplantar psoriasis, together with subtle ectodermal signs, can uncover SSPS in adulthood.
Uncommon cutaneous vascular lesions can present with overlapping clinical features, creating a diagnostic challenge. Histopathological examination is often essential to establish the diagnosis and exclude malignant mimics. We describe a patient with multiple erythematous papules and nodules affecting the head and neck. The clinical differential diagnoses included several benign and malignant vascular lesions. Histopathological examination demonstrated a proliferation of vascular channels lined by epithelioid endothelial cells with characteristic intraluminal protrusion, accompanied by a mixed inflammatory infiltrate rich in eosinophils. This case highlights the importance of collaboration between the dermatologist and dermatopathologist in the assessment of unusual vascular lesions for accurate diagnosis. The patient subsequently underwent surgical treatment with punch excision for smaller lesions and shave excision with cautery for larger lesions, with satisfactory clinical improvement and no reported recurrence to date. However, this condition can be challenging to treat and further research is needed to establish more effective and standardized treatment strategies.